10 papers · updated 2026-09-26 · Orthopaedic Oncology · All topics
The newest papers on osteosarcoma from the orthopaedic journals The Reduction reads, newest first, each with a one-line summary. The list is drawn from the digest’s archive and refreshed every week.
Get new Orthopaedic Oncology papers by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.
Multicomponent machine learning approach using multiple registries improves osteosarcoma survival prediction accuracy across diverse populations versus single data-set models.
In pediatric osteosarcoma patients, the Area Deprivation Index—unlike other social determinants of health measures—identified significant disparities in presentation delay, local recurrence, and overall survival.
In cell and mouse models, pulsed electromagnetic fields killed osteosarcoma cells via ferroptosis while promoting normal bone healing, suggesting a noninvasive adjuvant therapy after tumor resection.
A machine-learning-derived centromere gene signature predicts osteosarcoma prognosis and immune microenvironment status, while B3GALT4 was validated as a tumor suppressor that inhibits osteosarcoma cell proliferation and migration.
Single-cell transcriptomics identifies ADAMTS12 and RNASE1 as key drivers of osteosarcoma metastatic progression through malignant and immune cell signaling networks.
LL-37 peptide inhibits osteosarcoma through PTEN/AKT/mTOR pathway targeting cholesterol synthesis, offering promising therapeutic potential.
Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis.
Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis in lab and mouse models, providing preclinical rationale for drug repurposing.
Pediatric and young adult osteosarcoma survivors have high natural fertility rates comparable to the general population, reassuring patients and families during treatment counseling.
Higher tumor-associated neutrophil density predicts poor neoadjuvant chemotherapy response in osteosarcoma; biopsy-based model enables early risk stratification.
Age-related real-world treatment patterns and outcomes of localised, high-grade osteosarcoma.
Wide resection plus perioperative chemotherapy improves osteosarcoma survival at all ages; for patients over 40, guideline-concordant treatment remains the standard regardless of chemotherapy sequencing.
A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era
Osteosarcoma survival plateaued since 1980 despite improved limb salvage rates; new systemic strategies needed to advance outcomes for this lethal malignancy.
The Molecular Pathogenesis of Osteosarcoma: A Review
This 2011 review outlines the molecular pathogenesis of osteosarcoma and emerging translational research aimed at identifying targeted therapies to improve outcomes beyond current anatomically based staging and treatment.
Using Epidemiology and Genomics to Understand Osteosarcoma Etiology
This review discusses osteosarcoma's poorly understood etiology, examining epidemiologic risk factors (Paget disease, radiation, height) and emerging genomic associations without identifying a strong environmental cause.
Osteosarcoma has a complex, heterogeneous genomic landscape with recurrent copy number alterations but no definitive oncogene or tumor suppressor target yet identified for therapeutic exploitation.
In osteosarcoma, older age (>30) and larger tumors raised lung metastasis risk; surgery and chemotherapy improved survival while radiotherapy did not.
Home · All topics · Archive · Subscribe · FAQ
© 2026 The Reduction